WBIO — Wockhardt Bio AG Cashflow Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- CH₣1.04m
- -CH₣154.18m
- $297.12m
Annual cashflow statement for Wockhardt Bio AG, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | SAS | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -60.5 | -23.5 | 24.6 | 37.3 | -2.97 |
Depreciation | |||||
Non-Cash Items | -0.43 | 3.16 | -12 | 1.26 | -53.9 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 101 | 19.8 | 29.3 | 18.8 | 111 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 49.5 | 8.81 | 51.1 | 68.1 | 66.1 |
Capital Expenditures | -107 | -43 | -31 | -12.2 | -25 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | 49.2 | 32.1 | 0 | 19.8 | 33.6 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Cash from Investing Activities | -57.3 | -10.9 | -31 | 7.55 | 8.61 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 3.24 | 89.3 | -31.2 | -62.8 | -84.2 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -2.34 | 82.6 | -9.21 | 13.2 | -14.9 |